Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Rated Overweight in New Coverage at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $87.00 price target on the stock.

A number of other research analysts have also recently issued reports on KNSA. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.14.

Kiniksa Pharmaceuticals International Trading Up 0.8%

KNSA stock opened at $75.79 on Wednesday. Kiniksa Pharmaceuticals International has a 1-year low of $35.20 and a 1-year high of $82.94. The business’s 50 day moving average is $77.30 and its 200-day moving average is $61.67. The firm has a market cap of $5.91 billion, a P/E ratio of 78.13 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting the consensus estimate of $0.30. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. Sell-side analysts forecast that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G. Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. The trade was a 23.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 12.7% in the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after acquiring an additional 421,347 shares during the period. BNP Paribas Financial Markets grew its holdings in Kiniksa Pharmaceuticals International by 27.3% during the fourth quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after purchasing an additional 178,366 shares during the period. Dimensional Fund Advisors LP grew its holdings in Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after purchasing an additional 128,417 shares during the period. Spruce Street Capital LP increased its stake in Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after purchasing an additional 326,081 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company’s strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa’s primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older.